UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform, Questions About Near-Term Growth

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform, Questions About Near-Term Growth

Jefferies Keeps Optimer (OPTR) at Buy as CEO Makes Plans For Growth

October 9, 2012 1:10 PM EDT

Jefferies maintained a Buy rating on Optimer Pharmaceuticals (NASDAQ: OPTR), a company that focuses on the discovery, development and commercialization of anti-infective products, with one marketed drug for the treatment of diarrhea, DIFICID (fidaxomicin/OPT-80).

"While preannounced 3Q12 gross Dificid sales... More